SCHEMBL3033333

SCHEMBL3033333

Nc1ccc2c(c1)Nc1cc(N)ccc1S2(=O)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.50
MEN1 O00255 4/20 0.50
NOX1 Q9Y5S8 1/20 0.50
KDM4E B2RXH2 5/20 0.43
MAPT P10636 5/20 0.43
GAA P10253 4/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
CASP1 P29466 1/20 0.43
RECQL P46063 1/20 0.43
CASP7 P55210 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CA9 Q16790 5/20 0.40
CA12 O43570 4/20 0.40
POLB P06746 1/20 0.39
ABCC8 Q09428 2/20 0.36
KCNJ11 Q14654 2/20 0.36
MAOA P21397 1/20 0.35
CA1 P00915 3/20 0.34
CA2 P00918 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31348058 1.00 KMT2A (0.50) KMT2AMEN1NOX1KDM4EMAPT
SCHEMBL9243179 0.83 KMT2A (0.50) KMT2AMEN1NOX1KDM4EMAPT
SCHEMBL31614637 0.79 KMT2A (0.68) KMT2AMEN1NOX1KDM4EMAPT
SCHEMBL3600873 0.75 PLCG1 (0.61) KMT2AMEN1KDM4EMAPTGAA
SCHEMBL12253556 0.75 GPR3 (0.44) KMT2AMEN1KDM4EMAPTGAA
SCHEMBL20968301 0.71 MAPT (0.48) KMT2AMEN1KDM4EMAPTGAA
SCHEMBL3898921 0.71 MAPT (0.48) KMT2AMEN1KDM4EMAPTGAA
SCHEMBL4934590 0.70 CA12 (0.53) KMT2AMEN1KDM4EMAPTGAA
SCHEMBL30827024 0.70 CA12 (0.53) KMT2AMEN1KDM4EMAPTGAA
SCHEMBL29641986 0.70 CA12 (0.53) KMT2AMEN1KDM4EMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9067900-B2 Diaminophenothiazine compounds, a method for preparing same and uses thereof PHARMA HYDRO DEVELOPMENT—P.H.D. (FR) 2015-06-30 US disclosed
CN-101796041-B Diaminophenothiazine compounds, a method for preparing same and uses thereof PHARMA HYDRO DEV P H D 2013-05-22 CN disclosed
EP-2185531-B1 Diaminophenothiazine compounds, a method for preparing same and uses thereof PHARMA HYDRO DEV P H D (FR) 2012-07-25 EP disclosed
US-20100204215-A1 NOVEL DIAMINOPHENOTHIAZINE COMPOUNDS, A METHOD FOR PREPARING SAME AND USES THEREOF PHARMA HYDRO DEVELOPMENT - P.H.D. (FR) 2010-08-12 US disclosed
EP-2185531-A2 NOVEL DIAMINOPHENOTHIAZINE COMPOUNDS, A METHOD FOR PREPARING SAME AND USES THEREOF Pharma Hydro Development - P.H.D. (FR) 2010-05-19 EP disclosed
WO-2009044054-A2 NOVEL DIAMINOPHENOTHIAZINE COMPOUNDS, A METHOD FOR PREPARING SAME AND USES THEREOF PHARMA HYDRO DEVELOPMENT - P.H.D. (FR) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204215-A1 NOVEL DIAMINOPHENOTHIAZINE COMPOUNDS, A METHOD FOR PREPARING SAME AND USES THEREOF AOC1, DDT, DDC KMT2A 1144/4885MEN1 2765/4885NOX1 143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.